BHC
Price
$6.11
Change
+$0.08 (+1.33%)
Updated
Nov 24 closing price
Capitalization
2.26B
92 days until earnings call
Intraday BUY SELL Signals
HROW
Price
$38.75
Change
-$0.25 (-0.64%)
Updated
Nov 25, 10:30 AM (EDT)
Capitalization
1.44B
120 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BHC vs HROW

Header iconBHC vs HROW Comparison
Open Charts BHC vs HROWBanner chart's image
Bausch Health Companies
Price$6.11
Change+$0.08 (+1.33%)
Volume$2.54M
Capitalization2.26B
Harrow
Price$38.75
Change-$0.25 (-0.64%)
Volume$6.87K
Capitalization1.44B
BHC vs HROW Comparison Chart in %
BHC
Daily Signal:
Gain/Loss:
HROW
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BHC vs. HROW commentary
Nov 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a StrongBuy and HROW is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 25, 2025
Stock price -- (BHC: $6.11 vs. HROW: $39.00)
Brand notoriety: BHC: Notable vs. HROW: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BHC: 120% vs. HROW: 40%
Market capitalization -- BHC: $2.26B vs. HROW: $1.44B
BHC [@Pharmaceuticals: Generic] is valued at $2.26B. HROW’s [@Pharmaceuticals: Generic] market capitalization is $1.44B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 0 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • BHC’s FA Score: 0 green, 5 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than BHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 2 TA indicator(s) are bullish while HROW’s TA Score has 4 bullish TA indicator(s).

  • BHC’s TA Score: 2 bullish, 7 bearish.
  • HROW’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, HROW is a better buy in the short-term than BHC.

Price Growth

BHC (@Pharmaceuticals: Generic) experienced а -0.33% price change this week, while HROW (@Pharmaceuticals: Generic) price change was -3.20% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.04%. For the same industry, the average monthly price growth was -6.17%, and the average quarterly price growth was +16.63%.

Reported Earning Dates

BHC is expected to report earnings on Feb 25, 2026.

HROW is expected to report earnings on Mar 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.04% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BHC($2.26B) has a higher market cap than HROW($1.44B). HROW YTD gains are higher at: 16.244 vs. BHC (-24.194). BHC has higher annual earnings (EBITDA): 3.29B vs. HROW (32.1M). BHC has more cash in the bank: 1.31B vs. HROW (53M). HROW has less debt than BHC: HROW (231M) vs BHC (21B). BHC has higher revenues than HROW: BHC (10B) vs HROW (228M).
BHCHROWBHC / HROW
Capitalization2.26B1.44B157%
EBITDA3.29B32.1M10,246%
Gain YTD-24.19416.244-149%
P/E Ratio6.30N/A-
Revenue10B228M4,386%
Total Cash1.31B53M2,468%
Total Debt21B231M9,091%
FUNDAMENTALS RATINGS
BHC vs HROW: Fundamental Ratings
BHC
HROW
OUTLOOK RATING
1..100
6769
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
10046
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
5947
P/E GROWTH RATING
1..100
988
SEASONALITY SCORE
1..100
5048

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHC's Valuation (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for HROW (85). This means that BHC’s stock grew somewhat faster than HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (46) in the Pharmaceuticals Other industry is somewhat better than the same rating for BHC (100). This means that HROW’s stock grew somewhat faster than BHC’s over the last 12 months.

HROW's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as BHC (100). This means that HROW’s stock grew similarly to BHC’s over the last 12 months.

HROW's Price Growth Rating (47) in the Pharmaceuticals Other industry is in the same range as BHC (59). This means that HROW’s stock grew similarly to BHC’s over the last 12 months.

HROW's P/E Growth Rating (8) in the Pharmaceuticals Other industry is significantly better than the same rating for BHC (98). This means that HROW’s stock grew significantly faster than BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCHROW
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 6 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signal:
Gain/Loss:
HROW
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
REGRX20.630.21
+1.03%
Russell Inv Emerging Markets R6
NGJFX19.140.07
+0.37%
Nuveen Global Real Estate Securities R6
NWHVX11.450.01
+0.09%
Nationwide Geneva Mid Cap Gr A
MSIGX65.17N/A
N/A
Invesco Main Street A
TWVLX8.52N/A
N/A
American Century Value Inv

BHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHC has been loosely correlated with AMRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if BHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
+1.33%
AMRX - BHC
38%
Loosely correlated
+1.67%
VTRS - BHC
36%
Loosely correlated
+2.32%
AMPH - BHC
35%
Loosely correlated
+2.69%
NBIX - BHC
27%
Poorly correlated
-0.38%
HROW - BHC
27%
Poorly correlated
+0.23%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with OGI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+0.23%
OGI - HROW
37%
Loosely correlated
+5.74%
TKNO - HROW
35%
Loosely correlated
+8.37%
VTRS - HROW
34%
Loosely correlated
+2.32%
AMRX - HROW
31%
Poorly correlated
+1.67%
ELAN - HROW
31%
Poorly correlated
+3.78%
More